NEW ORLEANS--(BUSINESS WIRE)--ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics, Inc. (NasdaqGM: IMMU). Investor losses must relate to purchases of the Company’s shares between the expanded period of February 8, 2018 and January 18, 2019. This action is pending in the United States District Court for the District of New Jersey.
Get Help
Immunomedics investors should visit us at https://www.claimsfiler.com/cases/view-immunomedics-inc-securities-litigation-1 or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
On December 17, 2018, FDAnews.com reported that the Company had been cited by the FDA for violations including its handling of a data breach in August. Then, on January 17, 2019, Immunomedics disclosed receipt of a Complete Response Letter from the FDA for its product candidate, sacituzumab govitecan, relating to “Chemistry, Manufacturing and Control matters.”
On this news, the price of Immunomedics’ shares plummeted.
The first-filed case is Odeh v. Immunomedics, Inc. et al., 18-cv-17645.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.